The company launched its Chicken Selects chicken breast strips the following year and its line of Premium Chicken sandwiches in 2005 with similar success.
The results were shown in the first randomized phase II study comparing trastuzumab-DM1 (T-DM1) to Herceptin (trastuzumab) plus chemotherapy (docetaxel), the current standard of care for first line HER2-positive metastatic breast cancer.
Approved drugs for third-line use (meaning after two other drugs have been tried) in triple negative breast cancer only increase survival by 10% to 15%.